ReviewThe European respiratory journal2020
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.
Review in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 157 citations in OpenAlex.
- Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomised controlled trial.The European respiratory journal · 2026Trial
- Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial.Frontiers in immunology · 2024Trial
- Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials.Clinical and translational science · 2022Trial
- Restoring the Airway Barrier: How Targeting Eosinophilic Inflammation Shapes Epithelial Health and Clinical Remission in Asthma.Diagnostics (Basel, Switzerland) · 2026Review
- Cadherin-26 Promotes Airway Remodeling via Stabilizing Epithelial Expression of the Epidermal Growth Factor Receptor in Asthma.Allergy, asthma & immunology research · 2026Article
- Molecular Phenotyping Based on Blood Transcriptome-Associated Clusters in Asthma: Findings From Two Korean Asthma Cohorts.Allergy, asthma & immunology research · 2026Article
- Efficacy and Safety of IL-4Rα and IL-5/IL-5R Targeted Biologic Therapies in Type 2 Inflammatory Airway Diseases: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Review
- Review
- The Architecture of Deep Phenotyping in Asthma: Integrating Molecular, Metabolic, and Neuro-Hormonal Endotypes.International journal of molecular sciences · 2026Review
- Beyond inflammation: alarmins as critical drivers of pulmonary fibrosis.ERJ open research · 2026Review
- Exploring type 2 inflammation and disease complexity: perspectives of a clinical immunologist.Frontiers in immunology · 2026Review
- Identification of N4-Acetylcytidine-Related Biomarkers in Adult Asthma: An Integrative Multi-Omics Study.Journal of inflammation research · 2026Article
- Ginsenoside Rg1 attenuates asthma features in mice co-exposed to house dust mite allergen and diesel exhaust particle by modulating epithelial ILC2 interactions.Journal of ginseng research · 2026Article
- Integrated Single-Cell Profiling Reveals TL1A as a Biomarker and Driver of Type 2 Inflammation via Macrophage-Dependent Immunoregulation in Asthma.Research (Washington, D.C.) · 2026Article
- EV-associated non-coding RNAs in paediatric asthma airway remodelling: current mechanistic evidence and therapeutic perspectives.Frontiers in pharmacology · 2026Review
- Immunological Mechanisms Underlying Allergy Predisposition After SARS-CoV-2 Infection in Children.Cells · 2025Review
- Is Biologic Therapy an Effective Tool for Achieving Remission in Severe Asthma? A Retrospective Study in Central Romania.Life (Basel, Switzerland) · 2025Article
- Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases.Pharmaceutics · 2025Review
- A single-cell spatial chart of the airway wall reveals proinflammatory cellular ecosystems and their interactions in health and asthma.Nature immunology · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
Monoclonal antibody therapies have significantly improved treatment outcomes for patients with severe asthma; however, a significant disease burden remains. Available biologic treatments, including anti-immunoglobulin (Ig)E, anti-interleukin (IL)-5, anti-IL-5Rα and anti-IL-4Rα, reduce exacerbation rates in study populations by approximately 50% only. Furthermore, there are currently no effective treatments for patients with severe, type 2-low asthma. Existing biologics target immunological pathways that are downstream in the type 2 inflammatory cascade, which may explain why exacerbations are only partly abrogated. For example, type 2 airway inflammation results from several inflammatory signals in addition to IL-5. Clinically, this can be observed in how fractional exhaled nitric oxide (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.